Table 2 Common Signals (SOC level) and the number of preferred terms (PT).

From: Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

SOC

Number of PT

Nervous system disorders

30 (27.0%)

Psychiatric disorders

27 (24.3%)

Injury, poisoning and procedural complications

18 (16.2%)

General disorders and administration site conditions

10 (9.0%)

Product issues

7 (6.3%)

Respiratory, thoracic and mediastinal disorders

3 (2.7%)

Musculoskeletal and connective tissue disorders

3 (2.7%)

Gastrointestinal disorders

3 (2.7%)

Surgical and medical procedures

2 (1.8%)

Vascular disorders

1 (0.9%)

Social circumstances

1 (0.9%)

Skin and subcutaneous tissue disorders

1 (0.9%)

Renal and urinary disorders

1 (0.9%)

Metabolism and nutrition disorders

1 (0.9%)

Investigations

1 (0.9%)

Infections and infestations

1 (0.9%)

Eye disorders

1 (0.9%)

Total

101